These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 32947651)

  • 41. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
    Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
    Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognostic Value of
    Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
    Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era.
    Song GY; Yoon SE; Kim SJ; Kim JS; Koh Y; Moon JH; Oh SY; Lee HS; Shin HJ; Do YR; Lee WS; Kim DS; Park Y; Yhim HY; Yang DH
    Sci Rep; 2020 Jul; 10(1):11649. PubMed ID: 32669642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
    Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
    J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.
    Park S; Moon SH; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Ahn HK; Lee JY; Kim SJ; Choi JY; Kim WS
    Am J Hematol; 2012 Sep; 87(9):937-40. PubMed ID: 22730093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
    Alcoceba M; Stewart JP; García-Álvarez M; Díaz LG; Jiménez C; Medina A; Chillón MC; Gazdova J; Blanco O; Díaz FJ; Peñarrubia MJ; Fernández S; Montes C; Cabero A; Caballero MD; García-Sanz R; González M; González D; Tamayo P; Gutiérrez NC; García-Sancho AM; Sarasquete ME
    Br J Haematol; 2024 Jul; 205(1):109-121. PubMed ID: 38811363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
    Bolshinsky M; Nabhan C
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):655-661. PubMed ID: 27693134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
    Vercellino L; Cottereau AS; Casasnovas O; Tilly H; Feugier P; Chartier L; Fruchart C; Roulin L; Oberic L; Pica GM; Ribrag V; Abraham J; Simon M; Gonzalez H; Bouabdallah R; Fitoussi O; Sebban C; López-Guillermo A; Sanhes L; Morschhauser F; Trotman J; Corront B; Choufi B; Snauwaert S; Godmer P; Briere J; Salles G; Gaulard P; Meignan M; Thieblemont C
    Blood; 2020 Apr; 135(16):1396-1405. PubMed ID: 31978225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk Assessment in Diffuse Large B-Cell Lymphoma by Combining Baseline Metabolic Tumor Volume and Peking Criteria When Evaluating Series
    Yuan T; Zhang Y; Chen X; Wei M; Zhu H; Song Y; Yang Z; Zhu J; Wang X
    Front Oncol; 2022; 12():876581. PubMed ID: 35530320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of the prognostic value of interim fluorodeoxyglucose positron emission tomography/computed tomography in nasal-type extranodal natural killer/T-cell lymphoma.
    Chen X; Zhao S; Wang H; Fu C; Tian R; Zou L
    Quant Imaging Med Surg; 2021 Apr; 11(4):1220-1233. PubMed ID: 33816162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of the ΔSUV
    Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C
    J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.